Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose urokinase in diabetic foot syndrome with critical limb ischemia
2010-023426-20Phase 3Terminated
- Sponsor
- GWT-TUD
- Start
- Dec 2010
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of urokinase in diabetic foot ulcer (DFU), chronic limb-threatening ischemia (CLTI), arteriosclerosis obliterans and 1 more (2 arms), sponsored by GWT-TUD. Primary endpoint: Survival free of major amputation (overall). Started Dec 2010; status: terminated.
02
Drugs
urokinase
03
Conditions
diabetic foot ulcer (DFU)chronic limb-threatening ischemia (CLTI)arteriosclerosis obliteranstype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-023426-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023426-20.